MDVN got way ahead of itself price wise when it hit 140. I sold a chunk in the 120's mainly because it became too large of a percentage of my portfolio thanks to a 1000%+ rise in price. I started nibbling back again around 40 (post split) which was in hindsight too soon. As it went to high too fast it is now going down too far and too fast which is typically the case with a smallish biotech. If I didn't own any I would be loading up right now and am indeed adding a few more shares.
I am assuming you are a rookie investor as you are comparing apples to oranges. GILD's 5 year estimated growth is 12% per annum. MDVN's is 66%. Using your logic MDVN should be trading at 5 times GILD"s 7x earnings. Of course if you feel these estimates are wrong, which is very possible, you may invest accordingly. Biotechs have been slammed recently for many reasons and hardly at all for whatever promise they have in the future, which may make for a promising opportunity for those withs the guts to invest. Good luck.
I was hoping to end the year at a nice even $50 but that's not looking likely, although it is up nicely from yearly lows. Lets hope the new year brings more good news and a price that follows!
Judging from your getting only one thumbs down I would conclude that all those silly #$%$ posts are from one fool.
Couldn't resist a ten percent discount from yesterday considering revenue was already known a week ago and was already reflected in the price. I think in the next few trading days we will see a climb back up to yesterdays price unless the sector or market takes a fall.
Astellas is on a different calendar year for some reason but they increased previous 2015 sales projection in US by 3% and ex US by 14%.
Its funny how this stock got spanked when Astellas released sales last week than gets hit again this week after MDVN made it official. Obviously a lot of people not paying attention. I bought a little more this AM and will buy more if it drops much further.